13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001826434
Total reported value
$813.2M
$813.2M
22 檔
10.8%
According to the latest 13F quarterly dataset, Tri Locum Partners LP managed an equity portfolio of $813.2M at the end of Q1 2025, spanning 22 distinct U.S. exchange-listed positions.
In Q1 2025, Tri Locum Partners LP displayed an active expansion posture, initiating 22 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CI | THE Cigna Group | Stock-Healthcare | 12.48% | — | +81.10% | |
| 2 | MCK | Mckesson CORP | Stock-Healthcare | 9.30% | — | — | |
| 3 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 8.61% | — | — | |
| 4 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 8.37% | -1.21% | -56.21% | |
| 5 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 6.44% | — | -47.73% | |
| 6 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 6.44% | -3.08% | -20.23% | |
| 7 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 6.06% | +5.13% | -59.47% | |
| 8 | ARGX | Argenx Se - Adr | Stock-Healthcare | 5.42% | +1.51% | -69.37% | |
| 9 | GILD | Gilead Sciences Inc | Stock-Healthcare | 5.14% | — | — | |
| 10 | ILMN | Illumina Inc | Stock-Healthcare | 4.91% | — | — | |
| 11 | INSM | Insmed Inc | Stock-Healthcare | 3.99% | — | — | |
| 12 | NUVL | Nuvalent Inc-a | Stock-Other | 3.49% | -4.44% | EXIT | |
| 13 | ✓ | Merus N V | Stock-Other | 3.39% | — | -54.82% | |
| 14 | WGS | Genedx Holdings CORP | Stock-Other | 2.64% | — | -54.42% | |
| 15 | ASND | Ascendis Pharma A/S | Stock-Other | 2.58% | -8.20% | EXIT | |
| 16 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.27% | — | — | |
| 17 | EOLS | Evolus Inc | Stock-Other | 1.99% | — | -56.66% | |
| 18 | VERA | Vera Therapeutics Inc | Stock-Other | 1.85% | — | — | |
| 19 | STVN | Stevanato Group S.p.A. | Stock-Other | 1.84% | — | -84.34% | |
| 20 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.63% | — | +124.47% | |
| 21 | KRRO | Korro Bio Inc | Stock-Other | 1.15% | — | -10.98% | |
| 22 | ✓ | Femasys Inc | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CI | THE Cigna Group | — | NEW | New buy |
| 2 | MCK | Mckesson CORP | — | NEW | New buy |
| 3 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 4 | TEVA | Teva Pharmaceutical-sp Adr | — | NEW | New buy |
| 5 | INSP | Inspire Medical Systems Inc | — | NEW | New buy |
| 6 | MDGL | Madrigal Pharmaceuticals Inc | — | NEW | New buy |
| 7 | AXSM | Axsome Therapeutics Inc | — | NEW | New buy |
| 8 | ARGX | Argenx Se - Adr | — | NEW | New buy |
| 9 | GILD | Gilead Sciences Inc | — | NEW | New buy |
| 10 | ILMN | Illumina Inc | — | NEW | New buy |
| 11 | INSM | Insmed Inc | — | NEW | New buy |
| 12 | NUVL | Nuvalent Inc-a | — | NEW | New buy |
| 13 | ✓ | Merus N V | — | NEW | New buy |
| 14 | WGS | Genedx Holdings CORP | — | NEW | New buy |
| 15 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 16 | 2655787D | Blueprint Medicines CORP | — | NEW | New buy |
| 17 | EOLS | Evolus Inc | — | NEW | New buy |
| 18 | VERA | Vera Therapeutics Inc | — | NEW | New buy |
| 19 | STVN | Stevanato Group S.p.A. | — | NEW | New buy |
| 20 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 21 | KRRO | Korro Bio Inc | — | NEW | New buy |
| 22 | ✓ | Femasys Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Tri Locum Partners LP reported a total U.S. public equity portfolio value of $813.2M across 22 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CI, MCK, SLNOEUR) accounted for 10.8% of total reported equity market value during Q1 2025.
Top New Position Initiated
CI
市值: $24.3M
During Q1 2025, Tri Locum Partners LP's top holdings by market value included CI (12.5%)、MCK (9.3%)、SLNOEUR (8.6%). The largest single position, CI, represented 12.5% of total portfolio value.
In Q1 2025, Tri Locum Partners LP made 22 total portfolio adjustments, initiating 22 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.